Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Sep 17, 2024 08:13PM Form 4 MBX Biosciences, Inc. For: Sep 16 Filed by: ORBIMED ADVISORS LLC
Sep 16, 2024 08:37PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 16, 2024 08:30PM Form SC 13D/A Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Sep 10, 2024 04:13PM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Aug 29, 2024 06:15AM Form N-PX ORBIMED ADVISORS LLC For: Jun 30
Aug 16, 2024 08:54AM SINOVAC Reports Unaudited First Half of 2024 Financial Results
Aug 15, 2024 04:48PM Form SC 13D/A scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
Aug 15, 2024 04:39PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2024 04:07PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 13, 2024 04:12PM Form 144 Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 13, 2024 04:10PM Form 144 Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 9, 2024 04:10PM Form SC 13D/A Janux Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 18, 2024 05:33PM Form SC 13D/A Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jul 17, 2024 08:49PM Form 4 Terns Pharmaceuticals, For: Jul 15 Filed by: ORBIMED ADVISORS LLC
Jul 15, 2024 07:54PM Form 144 Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jul 15, 2024 07:52PM Form 144 Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jul 15, 2024 07:49PM Form 144 Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Jul 2, 2024 04:58PM Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 2, 2024 04:55PM Form 4 TELA Bio, Inc. For: Jun 28 Filed by: ORBIMED ADVISORS LLC
Jun 28, 2024 05:38PM Form 144 TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 20, 2024 05:16PM Form SC 13D/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 17, 2024 08:03AM Cure Rare Disease Expands Leadership Team and Board of Directors to Advance Mission
May 22, 2024 07:32PM Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
May 20, 2024 04:56PM Form SC 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 17, 2024 03:08PM Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 17, 2024 03:04PM Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 16, 2024 09:29AM Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 04:18PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 8, 2024 08:29PM Form 4 Corvus Pharmaceuticals, For: May 06 Filed by: ORBIMED ADVISORS LLC
May 8, 2024 07:55PM Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
May 3, 2024 05:17PM Form 4 NeuroPace Inc For: May 01 Filed by: ORBIMED ADVISORS LLC
May 1, 2024 07:45AM MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
Apr 29, 2024 05:53PM SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
Apr 26, 2024 05:03PM Form 4 NeuroPace Inc For: Apr 24 Filed by: ORBIMED ADVISORS LLC
Apr 23, 2024 06:39PM Form 4 NeuroPace Inc For: Apr 19 Filed by: ORBIMED ADVISORS LLC
Apr 18, 2024 05:10PM Form 4 NeuroPace Inc For: Apr 16 Filed by: ORBIMED ADVISORS LLC
Apr 15, 2024 05:25PM Form 4 NeuroPace Inc For: Apr 11 Filed by: ORBIMED ADVISORS LLC
Apr 12, 2024 05:35PM Form SC 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 12, 2024 04:12PM Form 3/A Traws Pharma, Inc. For: Apr 01 Filed by: ORBIMED ADVISORS LLC
Apr 4, 2024 04:40PM Form SC 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Apr 3, 2024 07:57PM Form 3 Traws Pharma, Inc. For: Apr 01 Filed by: ORBIMED ADVISORS LLC
Mar 28, 2024 04:34PM Form SC 13D Q32 Bio Inc. Filed by: ORBIMED ADVISORS LLC
Mar 27, 2024 05:17PM Form 3 Q32 Bio Inc. For: Mar 25 Filed by: ORBIMED ADVISORS LLC
Mar 22, 2024 05:00PM Form SC 13D/A Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
Mar 21, 2024 04:33PM Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 18, 2024 10:38AM Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference
Mar 8, 2024 04:35PM Form SC 13D/A NextCure, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 4, 2024 08:16PM Form 144 Verona Pharma plc Filed by: ORBIMED ADVISORS LLC
Mar 4, 2024 08:00AM Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors
Feb 29, 2024 08:00AM BlossomHill Therapeutics Closes $100 Million Series B Financing

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed